Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: A prospective study in 110 patients

Journal of Clinical Endocrinology and Metabolism

Volumn 85, Issue 6, 2000, Pages 2247-2252

  Colao, Annamaria ^a   Di Sarno, Antonella ^a   Landi, Maria Luisa ^a   Scavuzzo, Francesco ^b   Cappabianca, Paolo ^a   Pivonello, Rosario ^a   Volpe, Raffaele ^b   Di Salle, Francesco ^a   Cirillo, Sossio ^a   Annunziato, Lucio ^a   Lombardi, Gaetano ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CARDARELLI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; PROLACTIN; QUINAGOLIDE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL TRIAL; DRUG RESISTANCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTINOMA; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; DOPAMINE AGONISTS; DRUG RESISTANCE; ERGOLINES; FEMALE; HUMANS; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; PROLACTIN; PROLACTINOMA; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 17744389065     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.85.6.2247     Document Type: Article

References (24)

1. Cabergoline a review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinemia and inhibition of lactation
2. 3H]N-n-propylnorapomorphine
3. Prolactin lowering effect of a new ergoline derivative, FCE21336, in the rat: A comparison with bromocriptine
4. Growth hormone and prolactin excess
5. Medical treatment of prolactinomas
6. Long-lasting prolactin lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients
7. Effectiveness and tolerability of long-term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients
8. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea
9. Use of cabergoline in long-term treatment of hyperprolactinemic and acromegalic patients
10. Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine
11. Prolactinomas resistant to other doparnime agonists respond to chronic cabergoline treatment
12. Treatment of prolactinsecreting macroadenoma with once-a week dopamine agonist cabergoline
13. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage
14. Cabergoline: A first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma
15. Treatment of macroprolactinoma with cabergoline: A study of 85 patients
16. Resistance to bromocriptine in prolactinomas
17. Effects of new dopaminergic agonist CV 205-502 on plasma prolactin levels and tumor size in BRC-resistant prolactinomas
18. Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine
19. The effects of CV 205-502 in patients with hyperprolactinemia intolerant and/or resistant to bromocriptine
20. The effect of quinagolide and cabergoline, two selective dopamine receptor type-2 agonists, in the treatment of prolactinomas
21. Volume of pituitary macroadenomas: Assessment by MRI
22. Long-term treatment with cabergolme a new long-lasting ergoline derivative in idiopathic or tumorous hyperprolactinemia and outcome of drug-induced pregnancy
23. Cabergoline in the treatment of hyperprolactinemia: A study in 455 patients
24. Dopamine agonists and pituitary tumor shrinkage